1
|
Laszlo D, Marcacci GP, Martino M, Radice D, Rabascio C, Lucchetti B, Magarò A, Caime A, Menna S, Lionetti MT, Bertolini F. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis. Transfus Apher Sci 2020; 59:102819. [PMID: 32499108 DOI: 10.1016/j.transci.2020.102819] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 05/06/2020] [Accepted: 05/07/2020] [Indexed: 12/22/2022]
Abstract
BACKGROUND Upfront single or tandem ASCT still represents an integral part of treatment for patients with multiple myeloma. The combination of intermediate dose (ID) - cyclophosphamide plus G-CSF, has been considered the standard method as mobilization regimen. No prospective randomized clinical trials have compared efficacy and costs using ID - cyclophosphamide against a chemo-free mobilization strategy with G-CSF and plerixafor on demand. METHODS A prospective single arm of 20 patients enrolled in three Italian Centers mobilized with G-CSF plus plerixafor on demand was compared with a retrospective historical control arm of 30 patients mobilized with ID - cyclophosphamide (4 g/sqm) and G-CSF. Costs of the prospective arm was compared with the ones of the retrospective control arm with the aim to collect ≥4 × 106/kg CD34 + . The exploratory cost analysis was performed using microcosting specific inputs of G-CSF plus plerixafor on demand versus ID - cyclophosphamide + G-CSF considering pre-apheresis, peri-apheresis and post-apheresis session. RESULTS Mobilization with ID - cyclophosphamide and G-CSF resulted in a significantly higher CD34+ peak mean on day 1 yield (119 CD34+ μL vs 67.3; p = 0.06) and in total average CD34+ yield (mean collection 10.6 × 106/kg vs 5.8 × 106/kg; p = 0.004) compared to patients mobilized with G-CSF and plerixafor. There was no significant differences (p = 0.36) in the two groups of patients collecting ≥ 4 million CD34+/Kg with ID - cyclophosphamide and G-CSF (93.3 %) vs G-CSF and plerixafor (90.0 %). None of the patients undergoing G-CSF and plerixafor mobilization had febrile neutropenia compared with 7 patients who received ID - cyclophosphamide and G-CSF (0% vs 23 %, p = 0.03) who had a median of 5 days hospitalization (range 4-6). All patients proceeded to ASCT with a mean of 3.6 CD34+/kg infused for G-CSF and plerixafor arm and 4.4 CD34+/kg for the ID - cyclophosphamide + GCSF group (p = 0.37) with a median time to ANC and PLT engraftment not different in the two groups. Total costs of a mobilizing strategy using a combination of G-CSF and plerixafor on demand was 12.690 euros compared to 16.088 euros with ID - cyclophosphamide and G-CSF (p = 0.07); in particular, mobilization cost components were significantly lower for G-CSF and plerixafor vs G-CSF and ID - cyclophosphamide for hospital stay (3080 euros vs 9653 euros; p < 0.001) whereas for mobilizing agent, there was a significative difference with 5470 euros for G-CSF and plerixafor use due to the cost of plerixafor compared with 1140 euros for ID - cyclophosphamide and G-CSF treatment (P = 0.001). CONCLUSIONS Our data demonstrate that in patients with multiple myeloma eligible for ASCT, a chemo-free mobilization with G-CSF and plerixafor on demand is associated with efficacy in PBSC collection and optimal safety profile with similar average costs when compared to a chemo-mobilization with ID - cyclophosphamide. A prospective randomized multicenter study could address which is the most cost-effective strategy for this setting of patients. CLINICAL TRIAL REGISTRY Eudract Number EudraCT 2013-004690-27.
Collapse
Affiliation(s)
- D Laszlo
- Unità Di Mobilizzazione e Raccolta CSE, Divisione Di Laboratorio Di Ematoncologia Clinica, Istituto Europeo Di Oncologia IRCCS- Milano, Italy.
| | - G P Marcacci
- SS UTIE e Trapianto CSE, Dipartimento Ematologico, IRCCS, Istituto Nazionale Dei Tumori Fondazione "Sen G. Pascale" - Napoli, Italy
| | - M Martino
- UOC Centro Trapianti Midollo Osseo, Grande Ospedale BMM - Reggio Calabria, Italy
| | - D Radice
- Divisione Di Epidemiologia e Biostatistica, Italy
| | - C Rabascio
- Unità Di Mobilizzazione e Raccolta CSE, Divisione Di Laboratorio Di Ematoncologia Clinica, Istituto Europeo Di Oncologia IRCCS- Milano, Italy
| | - B Lucchetti
- Unità Di Mobilizzazione e Raccolta CSE, Divisione Di Laboratorio Di Ematoncologia Clinica, Istituto Europeo Di Oncologia IRCCS- Milano, Italy
| | - A Magarò
- Unità Di Mobilizzazione e Raccolta CSE, Divisione Di Laboratorio Di Ematoncologia Clinica, Istituto Europeo Di Oncologia IRCCS- Milano, Italy
| | - A Caime
- Unità Di Mobilizzazione e Raccolta CSE, Divisione Di Laboratorio Di Ematoncologia Clinica, Istituto Europeo Di Oncologia IRCCS- Milano, Italy
| | - S Menna
- Data Management - Istituto Europeo Di Oncologia IRCCS - Milano, Italy
| | - M T Lionetti
- Data Management - Istituto Europeo Di Oncologia IRCCS - Milano, Italy
| | - F Bertolini
- Unità Di Mobilizzazione e Raccolta CSE, Divisione Di Laboratorio Di Ematoncologia Clinica, Istituto Europeo Di Oncologia IRCCS- Milano, Italy
| |
Collapse
|
2
|
Mazzocco K, Masiero M, Mazza M, Radice D, Maisonneuve P, Pravettoni G. 189P Recommendation for “a start to move” program: A 8-week program of incremental physical activity in sedentary breast cancer survivors. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.128] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
3
|
Dicuonzo S, Leonardi M, Radice D, Morra A, Dell'Acqua V, Gerardi M, Rojas D, Surgo A, Cattani F, Cambria R, Fodor C, De Lorenzi F, Galimberti V, Orecchia R, Jereczek-Fossa B. EP-1344: Long-term reconstruction failure after postmastectomy RT to temporary expander or permanent implant. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31653-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
4
|
Bertani E, Fazio N, Radice D, Zardini C, Spinoglio G, Chiappa A, Ribero D, Biffi R, Partelli S, Falconi M. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. Eur J Surg Oncol 2017; 43:372-379. [DOI: 10.1016/j.ejso.2016.09.011] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 09/13/2016] [Accepted: 09/19/2016] [Indexed: 02/08/2023] Open
|
5
|
Verri E, Aurilio G, Rocca MC, Radice D, Cullurà D, De Cobelli O, Musi G, Jereczec B, Iacovelli R, Curigliano G, Nolè F. Modified BEP chemotherapy in patients with testicular germ-cell tumors treated at a Comprehensive Cancer Center. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw334.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Caini S, Radice D, Tosti G, Spadola G, Cocorocchio E, Ferrucci PF, Testori A, Pennacchioli E, Fargnoli MC, Palli D, Bazolli B, Botteri E, Gandini S. Risk of second primary malignancies among 1537 melanoma patients and risk of second primary melanoma among 52 354 cancer patients in Northern Italy. J Eur Acad Dermatol Venereol 2016; 30:1491-6. [PMID: 26990937 DOI: 10.1111/jdv.13645] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Revised: 01/07/2016] [Accepted: 02/15/2016] [Indexed: 12/22/2022]
Abstract
BACKGROUND The number of melanoma survivors has been increasing for decades due to early diagnosis and improved survival. These patients have an increased risk of developing a second primary cancer (SPC); also, melanoma is frequently diagnosed among patients firstly diagnosed with an extracutaneous malignancy. OBJECTIVE We evaluated the risk of developing a SPC among 1537 melanoma patients, and the risk of second primary melanoma (SPM) in 52 354 extracutaneous cancer patients, who were treated at the European Institute of Oncology in Milan, Italy, during 2000-2010. MATERIAL AND METHODS We calculated standardized incidence ratios (SIR) by applying gender-, age-, year- and region-specific reference rates to the follow-up time accrued between the diagnosis of the first and the second primary malignancies. RESULTS Seventy-six SPC were diagnosed during a median follow-up of 4 years, of which 49 (64%) during the first 2 years upon melanoma diagnosis. The SIR was increased for cancer of breast (4.10, 95% CI 2.79-6.03), thyroid (4.67, 95% CI 1.94-11.22), brain (6.13, 95% CI 2.30-16.33) and for non-Hodgkin lymphoma (3.12, 95% CI 1.30-7.50). During a median follow-up of 4 years, 127 SPM were diagnosed: thick lesions were less frequent than for melanoma diagnosed as first cancer. The SIR was increased for cancer of breast (5.13, 95%CI 3.91-6.73), thyroid (16.2, 95%CI: 5.22-50.2), head and neck (5.62, 95%CI 1.41-22.50), soft tissue (8.68, 95%CI 2.17-34.70), cervix (12.5, 95% CI 3.14-50.20), kidney (3.19, 95%CI 1.52-6.68), prostate (4.36, 95%CI 2.63-7.24) and acute myeloid leukaemia (6.44, 95%CI 2.42-17.20). CONCLUSIONS The most likely causes of these associations are the clustering of lifestyle risk factors in the same subgroups of population, mainly on a sociocultural basis and surveillance bias. This raises important questions about how to best follow cancer survivors by avoiding an inefficient use of resources and an excessive medicalization of these patients' lives.
Collapse
Affiliation(s)
- S Caini
- Unit of Cancer Risk Factors and Lifestyle Epidemiology, Institute for Cancer Research and Prevention, Florence, Italy
| | - D Radice
- Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
| | - G Tosti
- Division of Dermatoncological Surgery, European Institute of Oncology, Milan, Italy
| | - G Spadola
- Division of Dermatoncological Surgery, European Institute of Oncology, Milan, Italy
| | - E Cocorocchio
- Medical Oncology of Melanoma Unit, European Institute of Oncology, Milan, Italy
| | - P F Ferrucci
- Medical Oncology of Melanoma Unit, European Institute of Oncology, Milan, Italy
| | - A Testori
- Division of Dermatoncological Surgery, European Institute of Oncology, Milan, Italy
| | - E Pennacchioli
- Division of Melanoma and Muscle-Cutaneous Sarcomas, European Institute of Oncology, Milan, Italy
| | - M C Fargnoli
- Department of Dermatology, University of L'Aquila, L'Aquila, Italy
| | - D Palli
- Unit of Cancer Risk Factors and Lifestyle Epidemiology, Institute for Cancer Research and Prevention, Florence, Italy
| | - B Bazolli
- Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
| | - E Botteri
- Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
| | - S Gandini
- Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
| |
Collapse
|
7
|
Cella C, Spada F, Galdy S, Frezza A, Catapano M, Funicelli L, Mancuso P, Zorzino L, Radice D, Calleri A, Fazio N. Diffusion-MRI and angiogenic profiling in patients with advanced well-differentiated pancreatic neuroendocrine tumors treated with everolimus. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Galdy S, Aurilio G, Radice D, Spada F, Cella C, Frezza A, Nolè F, Fazio N. Carboplatin and etoposide chemotherapy in extrapulmonary poorly differentiated neuroendocrine carcinomas. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Piscosquito G, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Manganelli F, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laurà M, Calabrese D, Hughes RAC, Radice D, Solari A, Pareyson D. Responsiveness of clinical outcome measures in Charcot−Marie−Tooth disease. Eur J Neurol 2015; 22:1556-63. [DOI: 10.1111/ene.12783] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2015] [Accepted: 06/05/2015] [Indexed: 11/29/2022]
Affiliation(s)
- G. Piscosquito
- C. Besta Neurological Institute; IRCCS Foundation; Milan Italy
| | - M. M. Reilly
- MRC Centre for Neuromuscular Diseases; Institute of Neurology; University College London; London UK
| | - A. Schenone
- Department of Neurology, Ophthalmology and Genetics; University of Genoa; Genoa Italy
| | - G. M. Fabrizi
- Department of Neurological, Neuropsychological, Morphological and Motor Sciences; University of Verona; Verona Italy
| | - T. Cavallaro
- Department of Neurological, Neuropsychological, Morphological and Motor Sciences; University of Verona; Verona Italy
| | - L. Santoro
- Department of Neurosciences, Reproductive and Odontostomatological Sciences; University Federico II of Naples; Naples Italy
| | - F. Manganelli
- Department of Neurosciences, Reproductive and Odontostomatological Sciences; University Federico II of Naples; Naples Italy
| | - G. Vita
- Department of Neurosciences; University of Messina; Messina Italy
- Clinical Centre NEMO SUD; Fondazione Aurora Onlus; Messina Italy
| | - A. Quattrone
- Neurology Clinic; Neuroimaging Research Unit; National Research Council; Magna Graecia University; Catanzaro Italy
| | - L. Padua
- Department of Geriatrics; Neurosciences and Orthopaedics - Università Cattolica del Sacro Cuore; Rome; Don Carlo Gnocchi Foundation Milan Italy
| | - F. Gemignani
- Department of Neurosciences; University of Parma; Parma Italy
| | - F. Visioli
- Department of Pharmacological Sciences; University School of Pharmacy; Milan Italy
- Department of Molecular Medicine; University of Padua; Padua Italy
| | - M. Laurà
- MRC Centre for Neuromuscular Diseases; Institute of Neurology; University College London; London UK
| | - D. Calabrese
- C. Besta Neurological Institute; IRCCS Foundation; Milan Italy
| | - R. A. C. Hughes
- MRC Centre for Neuromuscular Diseases; Institute of Neurology; University College London; London UK
| | - D. Radice
- Department of Epidemiology and Biostatistics; European Institute of Oncology; Milan Italy
| | - A. Solari
- C. Besta Neurological Institute; IRCCS Foundation; Milan Italy
| | - D. Pareyson
- C. Besta Neurological Institute; IRCCS Foundation; Milan Italy
| | | |
Collapse
|
10
|
Veronesi G, Lazzeroni M, Szabo E, Brown PH, DeCensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Grimaldi MC, Spaggiari L, Bonanni B. Long-term effects of inhaled budesonide on screening-detected lung nodules. Ann Oncol 2015; 26:1025-1030. [PMID: 25672894 DOI: 10.1093/annonc/mdv064] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Accepted: 01/31/2015] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND A previously carried out randomized phase IIb, placebo-controlled trial of 1 year of inhaled budesonide, which was nested in a lung cancer screening study, showed that non-solid and partially solid lung nodules detected by low-dose computed tomography (LDCT), and not immediately suspicious for lung cancer, tended to regress. Because some of these nodules may be slow-growing adenocarcinoma precursors, we evaluated long-term outcomes (after stopping the 1-year intervention) by annual LDCT. PATIENTS AND METHODS We analyzed the evolution of target and non-target trial nodules detected by LDCT in the budesonide and placebo arms up to 5 years after randomization. The numbers and characteristics of lung cancers diagnosed during follow-up were also analyzed. RESULTS The mean maximum diameter of non-solid nodules reduced significantly (from 5.03 mm at baseline to 2.61 mm after 5 years) in the budesonide arm; there was no significant size change in the placebo arm. The mean diameter of partially solid lesions also decreased significantly, but only by 0.69 mm. The size of solid nodules did not change. Neither the number of new lesions nor the number of lung cancers differed in the two arms. CONCLUSIONS Inhaled budesonide given for 1 year significantly decreased the size of non-solid nodules detected by screening LDCT after 5 years. This is of potential importance since some of these nodules may progress slowly to adenocarcinoma. However, further studies are required to assess clinical implications. CLINICAL TRIAL NUMBER NCT01540552.
Collapse
Affiliation(s)
| | - M Lazzeroni
- Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
| | - E Szabo
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda
| | - P H Brown
- Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, USA
| | - A DeCensi
- Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy; Division of Medical Oncology, Ospedali Galliera, Genoa
| | - A Guerrieri-Gonzaga
- Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
| | - M Bellomi
- Division of Radiology, European Institute of Oncology, Milan; University of Milan, Milan
| | - D Radice
- Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
| | - M C Grimaldi
- Division of Radiology, European Institute of Oncology, Milan
| | - L Spaggiari
- Divisions of Thoracic Surgery; University of Milan, Milan
| | - B Bonanni
- Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
| |
Collapse
|
11
|
Piscosquito G, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laurà M, Calabrese D, Hughes RAC, Radice D, Solari A, Pareyson D. Is overwork weakness relevant in Charcot-Marie-Tooth disease? J Neurol Neurosurg Psychiatry 2014; 85:1354-8. [PMID: 24659795 DOI: 10.1136/jnnp-2014-307598] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND In overwork weakness (OW), muscles are increasingly weakened by exercise, work or daily activities. Although it is a well-established phenomenon in several neuromuscular disorders, it is debated whether it occurs in Charcot-Marie-Tooth disease (CMT). Dominant limb muscles undergo a heavier overload than non-dominant and therefore if OW occurs we would expect them to become weaker. Four previous studies, comparing dominant and non-dominant hand strength in CMT series employing manual testing or myometry, gave contradictory results. Moreover, none of them examined the behaviour of lower limb muscles. METHODS We tested the OW hypothesis in 271 CMT1A adult patients by comparing bilateral intrinsic hand and leg muscle strength with manual testing as well as manual dexterity. RESULTS We found no significant difference between sides for the strength of first dorsal interosseous, abductor pollicis brevis, anterior tibialis and triceps surae. Dominant side muscles did not become weaker than non-dominant with increasing age and disease severity (assessed with the CMT Neuropathy Score); in fact, the dominant triceps surae was slightly stronger than the non-dominant with increasing age and disease severity. DISCUSSION Our data does not support the OW hypothesis and the consequent harmful effect of exercise in patients with CMT1A. Physical activity should be encouraged, and rehabilitation remains the most effective treatment for CMT patients.
Collapse
Affiliation(s)
- G Piscosquito
- IRCCS Foundation, C. Besta Neurological Institute, Milan, Italy
| | - M M Reilly
- MRC Centre for Neuromuscular diseases, UCL Institute of Neurology, London, UK
| | - A Schenone
- Department of Neurology, Ophthalmology and Genetics, University of Genoa, Genoa, Italy
| | - G M Fabrizi
- Department of Neurological, Neuropsychological, Morphological and Motor Sciences, University of Verona, Verona, Italy
| | - T Cavallaro
- Department of Neurological, Neuropsychological, Morphological and Motor Sciences, University of Verona, Verona, Italy
| | - L Santoro
- Federico II University Department of Neurological Sciences, Naples, Italy
| | - G Vita
- Department of Neurosciences, University of Messina, and Clinical Centre NEMO SUD, Fondazione Aurora Onlus, Messina, Italy
| | - A Quattrone
- Neurology Clinic, Magna Graecia University, and Neuroimaging Research Unit, National Research Council, Catanzaro, Italy
| | - L Padua
- Department of Neurosciences, Catholic University and Don Gnocchi Foundation, Rome, Italy
| | - F Gemignani
- Department of Neurosciences, University of Parma, Parma, Italy
| | - F Visioli
- Department of Pharmacological Sciences, University School of Pharmacy, Milan, Italy IMDEA-Food, Madrid, Spain
| | - M Laurà
- MRC Centre for Neuromuscular diseases, UCL Institute of Neurology, London, UK
| | - D Calabrese
- IRCCS Foundation, C. Besta Neurological Institute, Milan, Italy
| | - R A C Hughes
- MRC Centre for Neuromuscular diseases, UCL Institute of Neurology, London, UK
| | - D Radice
- Department of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
| | - A Solari
- IRCCS Foundation, C. Besta Neurological Institute, Milan, Italy
| | - D Pareyson
- IRCCS Foundation, C. Besta Neurological Institute, Milan, Italy
| | | |
Collapse
|
12
|
Veronesi G, Lazzeroni M, Szabo E, Brown P, De Censi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Grimaldi M, Spaggiari L, Bonanni B. Long-Term Effects of Inhaled Budesonide on Screening-Detected Lung Nodules. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu351.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Spada F, Fazio N, Marconcini R, Antonuzzo A, Ricci S, Fontana A, Luppi G, Antonuzzo L, Di Costanzo F, Nobili E, Radice D, Galdy S, Sonzogni M, Pisa E, Barberis M. Real-World Study on Oxaliplatin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms : Clinical Outcomes and Preliminary Correlation with Biological Factors. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu345.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Giordano A, Lugaresi A, Confalonieri P, Granella F, Radice D, Trojano M, Martinelli V, Solari A, Giordano A, Martinelli V, Lugaresi A, Pucci E, Granella F, Trojano M, Solari A, Martinelli V, Pucci E, Messmer Uccelli M, Lugaresi A, Giordano A, Granella F, Solari A, Giordano A, Ferrari G, Martini F, Solari A, Radice D, D’Annunzio G, Lugaresi A, Farina D, Travaglini D, Pietrolongo E, Onofrj M, Torri Clerici V, Bonanno S, Brambilla L, Confalonieri P, Martinelli V, Radaelli M, Messina J, Comi G, Tortorella C, Luciannatelli E, Trojano M, Senesi C, Tsantes E, Granella F, Conti MZ, Rottoli MR, Bellantonio P, Fischetti M, Fantozzi R, Pala A, Traccis S, Di Battista G, Bianchi M, Benedetti MD, Gaetani L, Di Filippo M, Carolei A, Totaro R, Lanzillo R, Brescia Morra V, Coppola R, Cottone S, Chiavazza C, Cavalla P, Leonardi C, Aguglia U, Ziuliani C, Valla P, Sasanelli F, Valentino P, Quattrone A, Martino PG, Russo M, Vita G, Immovilli P. Implementation of the ‘Sapere Migliora’ information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. Mult Scler 2014; 20:1234-43. [DOI: 10.1177/1352458513519180] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2013] [Accepted: 12/11/2013] [Indexed: 11/16/2022]
Abstract
Background: The SIMS-Trial showed that the ‘Sapere Migliora’ information aid (IA) for newly diagnosed people with multiple sclerosis (PwMS) effectively improved patient knowledge and satisfaction with care. Objectives: The objectives of this paper are to assess the effectiveness of the IA in clinical practice and to compare the whole IA with the take-home booklet/website component alone. Methods: After updating the IA and replacing the CD with a website, a prospective, open-label non-randomised controlled trial compared the whole IA (group A, five SIMS-Trial centres) to take-home (group B, 16 centres). One month after the intervention, participants completed the MS Knowledge Questionnaire (MSKQ), care satisfaction questionnaire (COSM-R) (primary study outcomes), Hospital and Anxiety Depression Scale, and ad hoc questionnaire appraising the IA. Results: We enrolled 159 newly diagnosed PwMS (May 2012–March 2013). Drop-outs were four of 77 (5%, group A) and 11/82 (13%, group B). Primary endpoint (highest tertile both for MSKQ and COSM-R section 2 scores) was achieved by 38/77 (49%) group A and 33/82 (40%) group B ( p = 0.25). Attainment of secondary outcomes was also similar between groups. Conclusions: This study shows that the entire IA is not superior to the booklet/website alone, and that both are comparable in efficacy to the intervention arm of the SIMS-Trial. Trial registration number: ISRCTN78940214.
Collapse
Affiliation(s)
- A Giordano
- Unit of Neuroepidemiology, Foundation IRCCS Neurological Institute C. Besta, Italy
| | - A Lugaresi
- Department of Neuroscience and Imaging, University G. d’Annunzio of Chieti-Pescara, Italy
| | - P Confalonieri
- Department of Neuroimmunology, Foundation IRCCS Neurological Institute C. Besta, Italy
| | - F Granella
- Department of Neurosciences, Neurology Unit, University of Parma, Italy
| | - D Radice
- Division of Epidemiology and Biostatistics, European Institute of Oncology, Italy
| | - M Trojano
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Italy
| | - V Martinelli
- Department of Neurology, Scientific Institute Hospital San Raffaele, Italy
| | - A Solari
- Unit of Neuroepidemiology, Foundation IRCCS Neurological Institute C. Besta, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Radice D, Rezzolla L, Galeazzi F. Beyond second-order convergence in simulations of binary neutron stars in full general relativity. ACTA ACUST UNITED AC 2013. [DOI: 10.1093/mnrasl/slt137] [Citation(s) in RCA: 107] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
16
|
Catania C, Radice D, Spitaleri G, Adamoli L, Noberasco C, Delmonte A, Vecchio F, de Braud F, Toffalorio F, Goldhirsch A, De Pas T. The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study. Psychooncology 2013; 23:322-9. [DOI: 10.1002/pon.3424] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2013] [Revised: 09/06/2013] [Accepted: 09/11/2013] [Indexed: 01/29/2023]
Affiliation(s)
- C. Catania
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - D. Radice
- Epidemiology and Biostatistics Division; European Institute of Oncology; Milan Italy
| | - G. Spitaleri
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - L. Adamoli
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - C. Noberasco
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - A. Delmonte
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - F. Vecchio
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - F. de Braud
- Medical Oncology Unit 1; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - F. Toffalorio
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - A. Goldhirsch
- Department of Medicine; European Institute of Oncology; Milan Italy
| | - T. De Pas
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| |
Collapse
|
17
|
Landoni F, Zanagnolo V, Rosenberg P, Lopes A, Radice D, Bocciolone L, Aletti G, Parma G, Colombo N, Maggioni A. Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience. Gynecol Oncol 2013; 130:69-74. [DOI: 10.1016/j.ygyno.2013.02.038] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2012] [Revised: 02/24/2013] [Accepted: 02/27/2013] [Indexed: 10/27/2022]
|
18
|
Gardellini A, Gigli F, Babic A, Andreola G, Radice D, Sammassimo S, Martinelli G, Laszlo D. Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis. Ecancermedicalscience 2013; 7:327. [PMID: 23818939 PMCID: PMC3694838 DOI: 10.3332/ecancer.2013.327] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Indexed: 11/16/2022] Open
Abstract
PURPOSE Granulocyte colony-stimulating factors (G-CSFs), filgrastim and lenograstim, are recognised to be useful in accelerating engraftment after autologous stem cell transplantation. Several forms of biosimilar non-glycosylated G-CSF have been approved by the European Medicines Agency, with limited published data supporting the clinical equivalence in peripheral blood stem cell mobilisation and recovery after autologous stem cell transplantation. METHOD With the aim of comparing cost-effective strategies in the use of G-CSF after autologous stem cell transplantation, we retrospectively evaluated 32 patients consecutively treated with biosimilar filgrastim XM02 (Tevagrastim) and 26 with lenograstim. All patients received G-CSF (biosimilar or lenograstim) at a dosage of 5 mcg/kg/day subcutaneously from day 5 to absolute neutrophil count of 1500/mmc for three days. RESULTS The median time to absolute neutrophil count engraftment was 11 days for the filgrastim XM02 group and 12 days for the lenograstim group. As for platelets recovery, the median time was 12 days in both groups. The median number of G-CSF vials used for patients was 9.5 for Tevagrastim and 10.5 for lenograstim, reflecting a mean estimated cost of about 556.1 euros for Tevagrastim versus 932.2 euros for lenograstim (p< 0.001). The median days of febrile neutropenia were 1.5 and 1 for filgrastim XM02 and lenograstim, respectively. No adverse event related to the use of XM02 filgrastim was recorded. CONCLUSION In our experience, filgrastim XM02 and lenograstim showed comparable efficacy in shortening the period of neutropenia after cytoreduction and autologous stem cell transplantation, with a favourable cost effect for filgrastim XM02.
Collapse
Affiliation(s)
- A Gardellini
- Division of Haematoncology, European Institute of Oncology, Milan, Italy
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Giordano A, Ferrari G, Radice D, Randi G, Bisanti L, Solari A. Self-assessed health status changes in a community cohort of people with multiple sclerosis: 11 years of follow-up. Eur J Neurol 2012; 20:681-8. [DOI: 10.1111/ene.12028] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2012] [Accepted: 10/04/2012] [Indexed: 11/28/2022]
Affiliation(s)
- A. Giordano
- Unit of Neuroepidemiology; Foundation IRCCS Neurological Institute C. Besta; Milan Italy
| | - G. Ferrari
- Unit of Neuroepidemiology; Foundation IRCCS Neurological Institute C. Besta; Milan Italy
| | - D. Radice
- Division of Epidemiology and Biostatistics; European Institute of Oncology; Milan Italy
| | - G. Randi
- Unit of Epidemiology; Local Health Authority; Milan Italy
| | - L. Bisanti
- Unit of Epidemiology; Local Health Authority; Milan Italy
| | - A. Solari
- Unit of Neuroepidemiology; Foundation IRCCS Neurological Institute C. Besta; Milan Italy
| | | |
Collapse
|
20
|
Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol 2012. [PMID: 23200911 DOI: 10.1016/j.ygyno.2012.11.026] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OBJECTIVE The quality of first surgery is one of the most important prognostic factors in ovarian cancer patients. Pre-surgical distinction of benign and malignant pelvic mass plays a critical role in ovarian cancer management and survival. The aim of this study was to evaluate the clinical performance of ROMA algorithm and of CA125 and HE4 in the triage of patients with a pelvic mass undergoing surgery, in order to discriminate benign from malignant disease. METHODS Three hundred and forty-nine pre- and post-menopausal women, aged 18 years or older undergoing surgery because of a pelvic mass were enrolled: serum concentrations of CA125 and HE4 were determined and ROMA was calculated for each sample. RESULTS Median serum CA125 and HE4 levels were higher in patients with EOC compared to subjects with benign disease (p<0.0001). The resultant accuracy (using Receiver Operating Characteristics, ROC Area) values for HE4, CA125 and ROMA showed a good performance ranging from 89.8% for CA125 in pre-menopausal patients to 93.3% for ROMA in post-menopausal patients: AUC for ROMA resulted significantly higher in comparison to CA125 alone (93.3% vs 90.3%, p=0.0018) in post menopausal patients. A sub-analysis considering the 40 patients with endometrioid disease showed the highest accuracy of HE4 in these patients. CONCLUSIONS Data presented confirm the accuracy of HE4 and of the ROMA algorithm in the distinction of ovarian carcinoma from benign disease, with a trend towards better performance for ROMA than for CA125 alone, statistically significant in postmenopausal patients.
Collapse
Affiliation(s)
- M T Sandri
- Division of Laboratory Medicine, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Giordano A, Ferrari G, Radice D, Randi G, Bisanti L, Solari A. Health-related quality of life and depressive symptoms in significant others of people with multiple sclerosis: a community study. Eur J Neurol 2012; 19:847-54. [PMID: 22233289 DOI: 10.1111/j.1468-1331.2011.03638.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND AND PURPOSE Uncertain prognosis and modest treatment efficacy make multiple sclerosis (MS) a particularly difficult disease to adjust to for both patients and their significant others (SOs). Few studies have assessed health-related quality of life (HRQOL) and depressive symptoms in SOs of people with MS in the community. We assessed, and identified predictors of, HRQOL and depression in SOs of adults with MS. METHODS POSMOS (postal survey of self-assessed health in MS adults and SOs) is a longitudinal survey on a random sample of 251 people with MS in the Milan area. In 2010, SOs and contemporaneous controls completed the SF-36 and Chicago Multiscale Depression Inventory (CMDI). RESULTS Overall, 142 SOs (mean age 53.1 years; 50% women, 65% partners) and 120 controls (similar to SOs for sex and education, but older) participated. By multivariable modeling of the SO plus control population, SF-36 vitality was lower in SOs (proportional odds ratio 0.45; 95% confidence interval 0.28-0.70), women (0.41; 0.27-0.64), and older subjects (0.98; 0.97-0.99). SF-36 mental health was also lower in SOs (0.62; 0.40-0.96) and women (0.43; 0.28-0.67). Regarding MS characteristics associated with HRQOL and depression in SOs, severe disability [Expanded Disability Status Scale (EDSS > 6.5)] had no effect, whilst depressive symptoms (pathologic CMDI) negatively influenced most SF-36 and all CMDI scores in SOs. CONCLUSIONS SOs had significantly lower vitality and psychological well-being than controls, identifying a burden in being the companion of a person with MS. This burden was unrelated to physical compromise but associated with depressive symptoms in MS.
Collapse
Affiliation(s)
- A Giordano
- Unit of Neuroepidemiology, Foundation IRCCS Neurological Institute C. Besta, Milan, Italy
| | | | | | | | | | | | | |
Collapse
|
22
|
Bertani E, Chiappa A, Biffi R, Bianchi PP, Radice D, Branchi V, Spampatti S, Vetrano I, Andreoni B. Comparison of oral polyethylene glycol plus a large volume glycerine enema with a large volume glycerine enema alone in patients undergoing colorectal surgery for malignancy: a randomized clinical trial. Colorectal Dis 2011; 13:e327-34. [PMID: 21689356 DOI: 10.1111/j.1463-1318.2011.02689.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
AIM Recent meta-analyses and randomized clinical trials have concluded that mechanical bowel preparation (MBP) before elective colorectal surgery is not associated with a reduction of surgical site infection (SSI). The aim of this randomized clinical trial was to evaluate the impact of preoperative MBP for colon and rectal cancer surgery in comparison with a single glycerine enema. METHOD Patients scheduled for radical colorectal resection for malignancy with primary anastomosis were randomized to preoperative MBP (4 l of polyethylene glycol) (group 1, 114 patients) plus a glycerine 5% enema (2 l) or a single glycerine 5% enema (2 l) (group 2, 115 patients). The postoperative incidence of SSI was recorded prospectively. Patients undergoing minimally invasive surgery (laparoscopy or robotic) accounted for 55 and 51 in groups 1 and 2 respectively. RESULTS In all, 229 patients were included in the study, 114 in group 1 and 115 in group 2. At least one SSI was reported in 16 (14.0%) group 1 and in 20 (17.8%) group 2 patients (P=0.475). Perioperative mortality was nil. The incidence of SSI was comparable also in the 73 patients who had a low anterior resection (seven of 33 vs eight of 40, P=1.000), and for the 106 patients who underwent a minimally invasive procedure (nine of 55 vs four of 51, P=0.241). CONCLUSION A single large-volume glycerine enema is effective bowel preparation before colorectal resection whether performed by an open or minimally invasive technique.
Collapse
Affiliation(s)
- E Bertani
- Division of General and Laparoscopic Surgery, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Aurilio G, Sciandivasci A, Munzone E, Riva DF, Radice D, Bertolini F, Minchella I, Cullura D, Curigliano G, Zampino MG, Goldhirsch A, Nole F. First-line therapy with metronomic capecitabine (mC) plus docetaxel (D) followed by mC as maintenance for patients with HER2-negative metastatic breast cancer (MBC): Preliminary analysis of a monocentric phase II trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11547] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Passerini R, Ghezzi T, Sandri M, Radice D, Biffi R. Ten-year surveillance of nosocomial bloodstream infections: trends of aetiology and antimicrobial resistance in a comprehensive cancer centre. Ecancermedicalscience 2011; 5:191. [PMID: 22276048 PMCID: PMC3223944 DOI: 10.3332/ecancer.2011.191] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2010] [Indexed: 11/10/2022] Open
Abstract
Background: Bloodstream infections (BSIs) are one of the major life-threatening infectious conditions in cancer patients and are responsible for prolonged hospital stays, high healthcare costs and significant mortality. Several clinical trials have reported an improved survival in patients treated with appropriate empirical broad-spectrum antibiotic therapy. Early detection of pathogens and determination of their susceptibility are essential for the optimization of treatment. Variability between hospitals is substantial and requires the individual analysis of local trends. The aim of this study is to assess the local epidemiology of BSI in a single cancer centre over a 10-year period. Methods: Retrospective microbiological surveillance of all febrile/infective episodes occurring in oncological and surgical patients in a high-volume cancer centre between January 1999 and December 2008 were considered. Patients’ data were collected, processed and analyzed using the epidemiological resource of the Virtuoso Plus software (Metafora Informatica Srl, Milano, Italy). Spearman’s rank correlation coefficient, including the two-tailed test of significance, was used to investigate trends of incidence and rate of antibiotic resistance over the 10-year period. Results: A total of 13,058 blood cultures (BCs) were performed in 2,976 patients. BCs were positive in 2,447 tests, representing 740 infective/febrile episodes: 358 (48%) in medical oncology and 382 (52%) in surgical wards. Gram-positives were responsible for the majority of episodes in oncological and surgical divisions (about 63% and 55%, respectively). Gram-positives were also the most common organism in non-catheter-related BSIs (CRBSIs) both in medical oncology (75%) and in surgical divisions (50%). Enterococci showed an increased resistance to levofloxacin, from 5.6% to 25.7% (p = 0.02) and to erythromycin, from 41.7% to 61.4%, (p = 0.05). Similarly, coagulase negative staphylococci (CoNS) developed resistance to levofloxacin and ciprofloxacin, passing from 33.9% to 67.4% (p = 0.01) and from 5.6% to 25.7% (p = 0.01), respectively. Conclusions: Gram-positives are the main pathogens of BSIs; there is no difference in aetiology of CRBSIs between surgical and oncological patients. The lower incidence of gram-positive non-CRBSIs in surgical patients was probably due to gram-negative infections secondary to surgical complications.
Collapse
Affiliation(s)
- R Passerini
- Laboratory Medicine Unit, European Institute of Oncology, Milan, Italy
| | | | | | | | | |
Collapse
|
25
|
De Pas T, Rosati G, Spitaleri G, Boni C, Tucci A, Frustaci S, Scalamogna R, Radice D, Boselli S, Toffalorio F, Catania C, Noberasco C, Delmonte A, Vecchio F, de Braud F. Optimizing Clinical Care in Patients with Advanced Soft Tissue Sarcoma: A Phase II Study of a New Schedule of High-Dose Continuous Infusion Ifosfamide and Doxorubicin Combination. Chemotherapy 2011; 57:217-24. [DOI: 10.1159/000326466] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2010] [Accepted: 12/06/2010] [Indexed: 12/27/2022]
|
26
|
Catania C, De Pas TM, Goldhirsch A, Spitaleri G, Noberasco C, Delmonte A, Radice D, Adamoli L, Vecchio F, De Braud FG. Increasing awareness of patients with cancer faced with the choice of whether to participate in a phase I clinical trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Fazio N, Spada F, Squadroni M, Radice D, Di Meglio G, Terzi S, Luca F, Lazzari R, Pelosi G, De Braud FG. Multimodal treatment of nodal localizations from Merkel cell carcinoma with no identifiable primary site and distant metastases. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Meglio GD, Massacesi C, Radice D, Boselli S, Pelosi G, Squadroni M, Spada F, Lorizzo K, De Braud FG, Fazio N. Carboplatin with etoposide in patients with extrapulmonary “aggressive” neuroendocrine carcinoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13072] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Munzone E, Di Pietro A, Goldhirsch A, Minchella I, Verri E, Cossu Rocca M, Marenghi C, Curigliano G, Radice D, Adamoli L, Nolè F. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report. Breast 2010; 19:33-7. [DOI: 10.1016/j.breast.2009.10.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2009] [Revised: 10/02/2009] [Accepted: 10/06/2009] [Indexed: 12/20/2022] Open
|
30
|
Giordano A, Uccelli MM, Pucci E, Martinelli V, Borreani C, Lugaresi A, Trojano M, Granella F, Confalonieri P, Radice D, Solari A. The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. Mult Scler 2009; 16:100-11. [PMID: 19995834 DOI: 10.1177/1352458509352865] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
There are few studies on patient knowledge in multiple sclerosis (MS), and only two published questionnaires. The objective of this article was to develop and validate the MS Knowledge Questionnaire (MSKQ), a self-assessed instrument for newly diagnosed MS patients. Thirty multiple-choice statements, conceived to test MS knowledge, were produced by a multidisciplinary panel and pre-tested on three MS patients, resulting in an intermediate 26-item version. This was tested on 54 MS patients for internal consistency, content and construct validity (validation sample I). The final (25-item) MSKQ was a primary outcome measure in the SIMS-Trial on an information aid to newly diagnosed MS patients. Postal responses of SIMS-Trial participants to the MSKQ a month after intervention (validation sample II) were analysed. Median MSKQ scores in validation samples I and II were, respectively, 18 (range 9-23) and 17 (range 3-24). Acceptability, internal consistency (Kuder-Richardson-20 formula 0.76) and content validity were good. Educational attainment and receiving the information aid were the main independent predictors of MS knowledge. Other predictors were female sex (positive association) and disease duration (negative association). In conclusion, the MSKQ has good clinimetric properties and is sensitive to an educational intervention. We propose the MSKQ as a brief instrument for clinical practice and research.
Collapse
Affiliation(s)
- A Giordano
- Unit of Neuroepidemiology, Foundation IRCCS Neurological Institute C Besta, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Laszlo D, Pruneri G, Andreola G, Radice D, Calabrese L, Rafaniello PR, Nassi L, Sammassimo S, Alietti A, Agazzi A, Vanazzi A, Martinelli G. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin? Int J Surg Pathol 2009; 19:417-24. [PMID: 19793830 DOI: 10.1177/1066896909345596] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AIMS Diffuse large B-cell lymphomas (DLBCL) can be divided into different subgroups (germinal center B-cell-like [GCB] and non-GCB) according to their gene expression profiles. Immunohistochemistry has been proposed as a surrogate for identifying these subgroups, but data about its efficacy in providing prognostic information are conflicting. METHODS AND RESULTS This study retrospectively analyzed a series of 105 DLBCL, defined as GCB and non-GCB according to CD10, bcl-6, and MUM1 expression. All patients received a first-line anthracycline-based (CHOP-like) chemotherapy. A total of 50 patients (48%) were identified as GCB and 55 (52%) as non-GCB. The overall response rate was 89% (94/105), with 62 (59%) complete response. Disease progressions were equally distributed between the 2 subgroups and were not significantly different (P = .756) considering the primary site of involvement (nodal or extranodal). The median follow-up was 62 months (range 5-126 months). Overall survival at 5 years was not significantly different between the groups (P = .3468) and was 72.3% and 66.6% for GCB and non-GCB, respectively. CONCLUSION The results do not support the prognostic value of GCB and non-GCB immunohistochemical categories in DLBCL of both nodal and extranodal origin. Furthermore, a limited number of antigens may be not sufficient to identify the same patterns defined by cDNA microarray. Prospective studies are warranted to address this issue.
Collapse
Affiliation(s)
- D Laszlo
- European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Vanazzi A, Pruneri G, Crosta C, Grana C, Rizzo S, Radice D, Steffanoni S, Pinto A, Paganelli G, Martinelli G. 9207 Efficacy of 90Yttrium-ibritumomab tiuxetan in extranodal marginal-zone lymphoma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71898-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
33
|
Rabascio C, Laszlo D, Andreola G, Saronni L, Radice D, Rigacci L, Fabbri A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. Leuk Res 2009; 34:454-7. [PMID: 19647871 DOI: 10.1016/j.leukres.2009.07.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2009] [Revised: 06/25/2009] [Accepted: 07/02/2009] [Indexed: 11/18/2022]
Abstract
PURPOSE Resistance to nucleoside analogues agents is likely to be multifactorial and could involve a number of mechanisms affecting drug penetration, metabolism and targeting. In vitro studies of resistant human cell lines have confirmed that human concentrative nucleoside transporter 1 (hCNT1)-deficient cells display resistance. EXPERIMENTAL DESIGN We applied real-time PCR method to assess the mRNA expression of equilibrative and concentrative nucleoside transporter (hENT1, hCNT1), deoxycytidine and deoxyguanosine kinase (dCK, dGK), 5'-nucleotidase (5'-NT), ribonucleotide reductase catalytic and regulatory (RR1, RR2) subunits in bone marrow cells from 32 patients with Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) who received 2CdA-based chemotherapy. Responses to chemotherapy, were then correlated to the expression of these markers. RESULTS All 32 patients enrolled expressed lower levels of hCNT1 as compared to healthy donors. In univariate analysis, lower expression level of hCNT1 (p=0.0021) and RR2 (p=0.02) correlated with response to chemotherapy. In particular, patients with low levels of hCNT1 achieved inferior clinical response. No significant correlation between these genes expression and age, stage of disease was found. This study suggests that nucleotidase expression levels can be used to identify subgroups of WM and SLL patients who will likely respond differently to a 2CdA-based therapy.
Collapse
MESH Headings
- Adult
- Aged
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers, Tumor/genetics
- Cladribine/administration & dosage
- Female
- Gene Expression Regulation, Neoplastic/drug effects
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Male
- Membrane Transport Proteins/genetics
- Middle Aged
- Models, Biological
- Prognosis
- Rituximab
- Treatment Outcome
- Waldenstrom Macroglobulinemia/diagnosis
- Waldenstrom Macroglobulinemia/drug therapy
- Waldenstrom Macroglobulinemia/genetics
Collapse
Affiliation(s)
- C Rabascio
- Dept of Haematology, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Laszlo D, Rabascio C, Andreola G, Pruneri G, Raia V, Calabrese L, Radice D, Saronni L, Martinelli G. Chlorambucil – rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis. Leuk Lymphoma 2009; 48:437-8. [PMID: 17325914 DOI: 10.1080/10428190601078134] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
35
|
Bonanni B, Guerrieri-Gonzaga A, Radice D, Serrano D, Varricchio C, Ferretti S, Johansson H, Szabo E, Decensi A, Veronesi G. Randomized phase II trial of budesonide versus placebo in high-risk population with screening-detected lung nodules: Update on secondary endpoints. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1518 Background: Lung cancer phase II chemoprevention trials have not focused so far on the peripheral lung. CT discovers small, undetermined peripheral nodules, which may be preinvasive lesions. In a recent phase II trial the glucocorticoid Budesonide reduced peripheral nodules at spiral CT. Methods: We performed a randomized, double-blind, placebo-controlled, phase IIb clinical trial of inhaled budesonide in current (CS) or former smokers (FS) with CT-detected peripheral nodules. Primary endpoint: shrinkage effect on nodules. Secondary endpoints: decrease in size/number of the target lesions, modulation of tumor markers in sputum and plasma, toxicity, effect on pulmonary function. Two hundred and two subjects received 800μg budesonide (B) twice daily or placebo (P) for 1 year. CT scans at 0 and 12 months (mts), and clinical evaluation + serum/plasma collection at 0, 3, 6, and 12 months were performed. Subjects were stratified according to gender, smoking habits (CS vs. FS), and nodule characteristics (solid vs. non-solid). Results: Preliminary data had shown no shrinkage of the nodules in the B treated arm in a per subject analysis (primary objective). We present now results on serum markers (ultrasensitive C-reactive protein, CRP), emphysema and pulmonary function. As compared to baseline, CRP median levels show at 12 months a nonsignificant (p = 0.85) reduction: -0.25 ± 0.63 (B) vs. -1.16 ± 0.97 (P). 12-month values are significantly (p = 0.01) associated with baseline values and smoking status, with higher mean values at 12 months in FS (B 2.1 ± 2.0 vs. P 3.4 ± 1.9). Emphysema values at 12 months are significantly higher (p = 0.0022) in the B (+ 0.29 ± 0.06) versus P arm (+ 0.12 ± 0.07). This difference is not correlated to sex (p = 0.7062) and smoking status (p = 0.8044). As regards spirometry, no significant difference on FEV 1% and DLC/VA appears between arms at 12 months: median FEV 1% values 3.7 ± 1.0 for B versus 2.9 ± 1.0 for P (p = 0.6221); median DLC/VA increase of 0.3 ± 1.9 (B) versus decrease of -3.8 ± 1.6 (P) (p = 0.4191). Conclusions: A significant effect of B on ultrasensitive-CRP and pulmonary function has not been shown. CRP results may indicate the lack of systemic absorption of B. Emphysema appears slightly worse in the B arm, particularly in FS; this is worth further investigation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Bonanni
- European Institute of Oncology, Milan, Italy; National Cancer Institute, NIH, Bethesda, MD; E.O. Ospedali Galliera, Genoa, Italy
| | - A. Guerrieri-Gonzaga
- European Institute of Oncology, Milan, Italy; National Cancer Institute, NIH, Bethesda, MD; E.O. Ospedali Galliera, Genoa, Italy
| | - D. Radice
- European Institute of Oncology, Milan, Italy; National Cancer Institute, NIH, Bethesda, MD; E.O. Ospedali Galliera, Genoa, Italy
| | - D. Serrano
- European Institute of Oncology, Milan, Italy; National Cancer Institute, NIH, Bethesda, MD; E.O. Ospedali Galliera, Genoa, Italy
| | - C. Varricchio
- European Institute of Oncology, Milan, Italy; National Cancer Institute, NIH, Bethesda, MD; E.O. Ospedali Galliera, Genoa, Italy
| | - S. Ferretti
- European Institute of Oncology, Milan, Italy; National Cancer Institute, NIH, Bethesda, MD; E.O. Ospedali Galliera, Genoa, Italy
| | - H. Johansson
- European Institute of Oncology, Milan, Italy; National Cancer Institute, NIH, Bethesda, MD; E.O. Ospedali Galliera, Genoa, Italy
| | - E. Szabo
- European Institute of Oncology, Milan, Italy; National Cancer Institute, NIH, Bethesda, MD; E.O. Ospedali Galliera, Genoa, Italy
| | - A. Decensi
- European Institute of Oncology, Milan, Italy; National Cancer Institute, NIH, Bethesda, MD; E.O. Ospedali Galliera, Genoa, Italy
| | - G. Veronesi
- European Institute of Oncology, Milan, Italy; National Cancer Institute, NIH, Bethesda, MD; E.O. Ospedali Galliera, Genoa, Italy
| |
Collapse
|
36
|
Nole F, Munzone E, Bertolini F, Sandri MT, Petralia G, Adamoli L, Radice D, Cullura D, di Pietro A, Goldhirsch A. Circulating endothelial cells (CECs), progenitors (CEPs), and circulating tumor cells (CTCs) for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic oral vinorelbine (oV): Preliminary results. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e14572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14572 Background: Metronomic administration of chemotherapy given once or more per week with no extended gaps was shown to be effectively anti-angiogenic, causing growth arrest or apoptosis of endothelial cells in tumor neo-vessels. Preclinical and clinical studies indicate that ultra-low concentrations of various microtubule inhibitors inhibit proliferation or migration of endothelial cells. We investigated in a phase II study the activity of metronomic administration of oV in ABC, kinetics and response prediction of CECs, CEPs, CTCs and of other biomarkers of angiogenesis (soluble VEGF, VEGFr2, TSP1, bFGF). CT perfusion scans were also performed. Methods: From February 2008, 47 pts with ABC received oV (50 mg/die TTW). Currently 20 pts are evaluable for both activity and biomarker assessment. Baseline levels of biomarkers of angiogenesis were correlated with clinical response. Results: Shown in Table . Conclusions: We found that the baseline value of apoptotic cells (expressed as % of total cells) was significantly correlated with outcome. The baseline total, viable, and apoptotic CEC count and CTCs might provide an indirect measure for angiogenic turnover and an indicator of better response to anti-angiogenic therapy, supporting the use of metronomic treatments in patients expressing high levels of baseline CECs. Updated results will be presented together with correlation with perfusion CT scan and levels of CTCs. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Nole
- European Institute of Oncology, Milan, Italy
| | - E. Munzone
- European Institute of Oncology, Milan, Italy
| | | | | | - G. Petralia
- European Institute of Oncology, Milan, Italy
| | - L. Adamoli
- European Institute of Oncology, Milan, Italy
| | - D. Radice
- European Institute of Oncology, Milan, Italy
| | - D. Cullura
- European Institute of Oncology, Milan, Italy
| | | | | |
Collapse
|
37
|
Biffi R, Orsi F, Pozzi S, Pace U, Bonomo G, Monfardini L, Della Vigna P, Rotmensz N, Radice D, Zampino MG, Fazio N, de Braud F, Andreoni B, Goldhirsch A. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol 2009; 20:935-40. [PMID: 19179550 DOI: 10.1093/annonc/mdn701] [Citation(s) in RCA: 168] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Central venous access is extensively used in oncology, though practical information from randomized trials on the most convenient insertion modality and site is unavailable. METHODS Four hundred and three patients eligible for receiving i.v. chemotherapy for solid tumors were randomly assigned to implantation of a single type of port (Bard Port, Bard Inc., Salt Lake City, UT), through a percutaneous landmark access to the internal jugular, a ultrasound (US)-guided access to the subclavian or a surgical cut-down access through the cephalic vein at the deltoid-pectoralis groove. Early and late complications were prospectively recorded until removal of the device, patient's death or ending of the study. RESULTS Four hundred and one patients (99.9%) were assessable: 132 with the internal jugular, 136 with the subclavian and 133 with the cephalic vein access. The median follow-up was 356.5 days (range 0-1087). No differences were found for early complication rate in the three groups {internal jugular: 0% [95% confidence interval (CI) 0.0% to 2.7%], subclavian: 0% (95% CI 0.0% to 2.7%), cephalic: 1.5% (95% CI 0.1% to 5.3%)}. US-guided subclavian insertion site had significantly lower failures (e.g. failed attempts to place the catheter in agreement with the original arm of randomization, P = 0.001). Infections occurred in one, three and one patients (internal jugular, subclavian and cephalic access, respectively, P = 0.464), whereas venous thrombosis was observed in 15, 8 and 11 patients (P = 0.272). CONCLUSIONS Central venous insertion modality and sites had no impact on either early or late complication rates, but US-guided subclavian insertion showed the lowest proportion of failures.
Collapse
Affiliation(s)
- R Biffi
- Division of Abdomino-Pelvic Surgery, European Institute of Oncology, via Ripamonti 435, I-20141 Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Didier F, Radice D, Gandini S, Bedolis R, Rotmensz N, Maldifassi A, Santillo B, Luini A, Galimberti V, Scaffidi E, Lupo F, Martella S, Petit JY. Does nipple preservation in mastectomy improve satisfaction with cosmetic results, psychological adjustment, body image and sexuality? Breast Cancer Res Treat 2008; 118:623-33. [PMID: 19003526 DOI: 10.1007/s10549-008-0238-4] [Citation(s) in RCA: 198] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2008] [Accepted: 10/27/2008] [Indexed: 11/30/2022]
Abstract
We investigated the influence of nipple areolar complex (NAC) sparing in mastectomy, on patient satisfaction with cosmetic results, body-image, sexuality and psychological well-being. We developed a specific questionnaire and compared two groups of women who underwent radical mastectomy with immediate breast reconstruction (IBR). Between 2004 and 2006, 310 women with NAC preservation and 143 patients with successive NAC reconstruction were mailed the questionnaire at follow-up 1 year after definitive complete breast reconstruction surgery. 256 questionnaires was available. Our results showed significant differences in favour of the NAC sparing group regarding body image (difficulty in looking at themselves naked and being seen naked by their partners after surgery, P = 0.001 and P = 0.003, respectively); regarding satisfaction with the appearance of the nipple (P < .0001) and with the sensitivity of the nipple (P = 0.001); regarding the feeling of mutilation (P = 0.003). NAC sparing in mastectomy has a positive impact on patient satisfaction, body image and psychological adjustment.
Collapse
Affiliation(s)
- F Didier
- Psycho-Oncology Unit, Department of Medicine (Prof. A. Goldhirsch), European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Passerini R, Riggio D, Radice D, Bava L, Cassatella C, Salvatici M, Zorzino L, Sandri MT. Interference of antibiotic therapy on blood cultures time-to-positivity: analysis of a 5-year experience in an oncological hospital. Eur J Clin Microbiol Infect Dis 2008; 28:95-8. [DOI: 10.1007/s10096-008-0594-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2008] [Accepted: 06/23/2008] [Indexed: 11/30/2022]
|
40
|
Catania C, Zagonel V, Fosser V, La Verde N, Bertetto O, Iacono C, Venturini M, Radice D, Adamoli L, Boccardo F. Opinions concerning euthanasia, life-sustaining treatment and acceleration of death: results of an Italian Association of Medical Oncology (AIOM) survey. Ann Oncol 2008; 19:1947-54. [PMID: 18556665 DOI: 10.1093/annonc/mdn381] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Advance directives, acceleration of death, euthanasia and 'life-sustaining treatment' have sparked much heated debate among the media, the public, doctors and political leaders. We evaluate the personal opinions of Italian Association of Medical Oncology (AIOM) members. PATIENTS AND METHODS A 30-item questionnaire was developed and delivered to all 1,832 AIOM members. RESULTS Six-hundred and eighty-five (37%) oncologists completed and returned the questionnaires. Sixty-three per cent felt culturally and psychologically prepared to face these issues. Fifty-four per cent believed that what had been decided while the patient enjoyed good health is no longer applicable in an advanced state of terminal illness. Thirty-nine per cent believed that doctors should abide by these directives, while 49% believed that this should be discussed on a case-by-case basis. Fourteen per cent of oncologists were favourable towards euthanasia and 42% only in particular circumstances. Fifty-six per cent had received at least one request for accelerating death: 15% consented, 50% discussed it with the patient and 31% refused. CONCLUSION Advance directives, euthanasia, accelerated death and life-sustaining treatment represent considerable challenges for Italian oncologists. Although prepared to face these issues, AIOM members ask for a debate within the medical world and for a shared judicial regulation.
Collapse
Affiliation(s)
- C Catania
- New Drugs Development Unit, Medical Oncology Division, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Catania C, Medici M, Magni E, Munzone E, Cardinale D, Adamoli L, Sanna G, Minchella I, Radice D, Goldhirsch A, Nolè F. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann Oncol 2007; 18:1969-75. [PMID: 17846020 DOI: 10.1093/annonc/mdm372] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Trastuzumab (T) combined with i.v. vinorelbine (i.v.VNR) is an active regimen for patients with advanced breast cancer (ABC). In order to further improve quality of life of patients undergoing treatment for ABC, a new regimen using oral vinorelbine (oVNR) (d1 + d3) plus q3wks T was tested (ToVNR). PATIENTS AND METHODS Thirty-nine patients with ABC, human epidermal growth factor receptor 2/neu 3+ or FISH positive received 288 treatment cycles with T 6 mg/kg (loading dose, 8 mg/kg) on d1 and oVNR 55 mg/m(2) on d1 + d3, q3wks until disease progression or unacceptable toxicity. RESULTS Thirty-seven patients and 286 treatment cycles were evaluated (two patients were lost to follow-up). Treatment was very well tolerated. Two patients had complete response (CR), 14 partial response (PR), 17 stable disease (SD) and four disease progression (PD) (overall response rate: 43%). Clinical benefit rate (CR + PR + SD >24 months) was 73%. Median time to progression was 8.9 months (range 2-27) and median duration of response was 10.9 months (range 2-27). CONCLUSIONS The ToVNR combination is active and very well tolerated. It favorably compares with the combination of T and weekly i.v. administered VNR, allowing a more convenient once every three weeks hospital admission and leaving patients and care providers free from the unpleasant effect of i.v.VNR.
Collapse
Affiliation(s)
- C Catania
- Division of Medical Oncology, Unit for Medical Care, Department of Medicine, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Solari A, Laurà M, Salsano E, Radice D, Pareyson D. Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. Neuromuscul Disord 2007; 18:19-26. [PMID: 17964785 DOI: 10.1016/j.nmd.2007.09.006] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2007] [Revised: 07/12/2007] [Accepted: 09/06/2007] [Indexed: 10/22/2022]
Abstract
We assessed inter- and intra-rater reliability of outcome measures in Charcot-Marie-Tooth disease (CMT) patients. In 40 CMT patients, we assessed reliability of Overall Neuropathy Limitations Scale (ONLS), 10-m timed walk (T10MW), 9-hole-peg test (9-HPT), maximal voluntary isometric contraction (MVIC) of arm (elbow flexion, hand-grip, and three-point pinch) and leg (knee extension, foot dorsiflexion/plantar flexion). Reliability was substantial for ONLS, excellent for T10MW and 9-HPT. For MVIC, inter and intra-rater reliability was excellent for hand contractions; for leg contractions, intra-rater agreement was moderate to substantial, whereas inter-rater agreement was poor. An ad hoc device was produced to immobilize the foot and MVIC reliability was re-assessed in 26 CMT patients, resulting in excellent inter-rater and intra-rater reliability for foot dorsiflexion, and clear inter-rater improvement for foot plantar flexion. All outcome measures appear adequate for CMT assessment. Use of an immobilization device improves foot MVIC reliability, preventing biased findings in patients with greater strength.
Collapse
Affiliation(s)
- A Solari
- Neuroepidemiology Unit, IRCCS Foundation, C. Besta Neurological Institute, Via Celoria 11, 20133 Milan, Italy.
| | | | | | | | | | | |
Collapse
|
43
|
Bellomi M, Rizzo S, Travaini LL, Bazzi L, Trifirò G, Zampino MG, Radice D, Paganelli G. Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer. Radiol Med 2007; 112:681-90. [PMID: 17657420 DOI: 10.1007/s11547-007-0172-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2006] [Accepted: 07/27/2006] [Indexed: 01/11/2023]
Abstract
PURPOSE The aim of this study was to compare the diagnostic value of multidetector computed tomography (MDCT) and F18-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) for the detection of local and distant recurrence in patients operated on for rectal cancer. MATERIALS AND METHODS Sixty-seven patients who underwent radical surgery for rectal cancer and were followed up with FDG-PET/CT and MDCT were included in this retrospective study. The FDG-PET/CT and MDCT findings were independently compared with histological sampling or 2 years' follow-up. RESULTS Local recurrence occurred in 15/67 patients. MDCT diagnosed local recurrence in 15/15 cases and FDG-PET/CT in 14/15. Sensitivity and specificity were 100% and 98% for MDCT and 93% and 98% for FDG-PET/CT, respectively. Hepatic lesions were found in 17/67 patients. All hepatic metastases were detected by both techniques. Pulmonary metastases occurred in 8/67 patients: they were correctly identified in all cases by MDCT and in 6/8 by FDG-PET/CT. CONCLUSIONS MDCT and FDG-PET/CT showed high sensitivity and specificity for the detection of local recurrence of rectal cancer. Both techniques were equally accurate for the detection of hepatic metastases. MDCT showed slightly higher sensitivity and positive predictive value in detecting pulmonary metastases compared with FDG-PET/CT.
Collapse
Affiliation(s)
- M Bellomi
- Facoltà di Medicina e Chirurgia, Università degli Studi di Milano, Via Festa del Perdono 7, I-20122 Milano, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
The Paced Auditory Serial Addition Test (PASAT), most used neuropsychological test in people with multiple sclerosis (pwMS), is available as PASAT-3 and more difficult PASAT-2. We determined PASAT performance in 105 pwMS and 105 matched controls and assessed the utility of a shortened PASAT-3 version. Qualitative and quantitative analyses were performed, the latter involving assessment of dyads (two consecutive correct responses) and singles (correct response between two omitted responses). Based on provisional results we then calculated the sensitivity of the first 20 items of PASAT-3 in relation to the full version. Mean PASAT-2 and 3 total score, dyads and singles differed significantly (P < or = 0.0002) in pwMS and controls, due to more omissions in pwMS, number and type of incorrect answers did not differ. Differences between pwMS and controls were highly significant for the first 50, 40, 30 and 20 responses of the PASAT-3. The sensitivity of the first 20 items of PASAT-3 was 87% (95% CI 0.70-1.00). PASAT-3 and PASAT-2 effectively discriminate pwMS from controls. Use of the first 20 items of PASAT-3 appears as a highly useful PASAT-3 version as it retains the discriminative value and sensitivity of the full version yet is quicker to administer and less demanding.
Collapse
Affiliation(s)
- A Solari
- Neuroepidemiology Unit, 'C. Besta' Neurological Institute, Milan, Italy.
| | | | | | | |
Collapse
|
45
|
Catania C, De Pas TM, Goldhirsch A, Radice D, Adamoli L, Medici M, Verri E, Marenghi C, de Braud F, Nolè F. Understanding the choice of participating in clinical trials. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.9091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9091 Background: The choice of whether to participate in a clinical trial by patients (pts) with cancer can be influenced, beyond trial information, by patient's own emotional and cultural properties, including past history as well as prejudices. Our hypothesis was that a better knowledge of these cultural and emotional features might be useful to improve patients-doctor dialogue, leading patients to a more conscious motivation to make the choice. Methods: We developed a 17-items, multiple-choice and open-answer questionnaire, to capture motivations for participating, or declining to take part, in clinical trials. Further information included family relationships, schooling and clinical symptoms. Patients were required to have advanced lung or breast cancer and to have never discussed participation in a clinical trial. Results: The questionnaire was answered by all the 42 pts who received it. Eighty-three percent of pts were positive about their participation. Trust in the investigator (43%) or in the Institute (21%) and hope to receive a new chance for cure (71%), both for themselves and for others, were a major motivation for a positive answer. Forty-eight percent thought participation in a clinical trial as a sign that no other “standard” treatments are available; 19% were worried of unknown side effects and 76% considered detailed information on expected toxicity to be helpful in making the decision. Sixty percent of patients were afraid of losing “precious time” by participating in a trial; 9% felt exploited as “guinea pigs” and 31% had a some degree of fear that a clinical trial is primarily motivated by economical interests. The most important reasons for accepting an oral experimental drug were its easy use (46%) and having more freedom (36%) Conclusions: Italian patients with advanced breast or lung cancer positively viewed participation in a clinical trial. Several hopes, prejudices and fears have been captured by the questionnaire, which might lead to improve the informed consent documentation and the consciousness of patients in taking their choice. Validation of the findings in a larger cohort of patients will lead to a study on the effect of a specific intervention on informing patients about clinical research. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Catania
- European Institute of Oncology, Milan, Italy
| | | | | | - D. Radice
- European Institute of Oncology, Milan, Italy
| | - L. Adamoli
- European Institute of Oncology, Milan, Italy
| | - M. Medici
- European Institute of Oncology, Milan, Italy
| | - E. Verri
- European Institute of Oncology, Milan, Italy
| | - C. Marenghi
- European Institute of Oncology, Milan, Italy
| | - F. de Braud
- European Institute of Oncology, Milan, Italy
| | - F. Nolè
- European Institute of Oncology, Milan, Italy
| |
Collapse
|
46
|
Vanazzi A, Ferrucci P, Grana C, Cremonesi M, Chinol M, Papi S, Calabrese L, Radice D, Paganelli G, Martinelli G. High dose 90Yttrium ibritumomab tiuxetan with PBSC support in refractory-resistant NHL patients: Preliminary results of a phase I/II study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7587] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7587 Background: Therapeutic options are limited in the treatment of relapsing NHL pts not suitable to HDCT. 90Yttrium ibritumomab tiuxetan (Zevalin) is active in DLBCL at 0.4 mCi/kg, but duration of response is usually short. We present feasibility and toxicity results of a phase I/II study of HD-Zevalin with PBSC support in resistant-refractory NHL pts. From 04/04 to 11/05, 14 pts were enrolled. Median age was 68ys. 13/14 pts had advanced stage disease (III/IV) at diagnosis. 8 DLBCL, 4 MCL, 1 FL G3, 1 transformed MZL. Median number of prior therapies were 3, including rituximab, RT and HD-CT. Methods: 3 dose levels were fixed: 0.8, 1.2, 1.5 mCi/kg. 4 pts received 0.8, 4 pts 1.2 and 6 pts 1.5 mCi/kg. 1wk prior to Zevalin all pts underwent dosimetry: if no abnormal uptake was observed they received the planned dose. On d13 pts received PBSC previously harvested. On d28 from reinfusion (+41 from Zevalin) engraftment was considered to be delayed if ANC <1.0×109/L or PLT<20.0×109/L. Results: Dosimetry showed acceptable radiation-absorbed doses to uninvolved organs, reaching max 20Gy. Only 1pt received 30Gy to the liver without developing toxicity. The median radiation-activity delivered was 90 mCi (range 57–150): 8 pts received a dose within 80 and 100 and 6 pts >100 mCi. Mean dose to red marrow: 0.8±0.2 mGy/MBq. All pts but 1 engrafted promptly. PLT/ANC count nadirs were observed 21/17 days after Zevalin (median values: 11×109/L and 0.01×109/L). No statistically significant difference in terms of hematological toxicity exists in PLT-recovering for pts receiving 1.5 mCi/kg and it is probably influenced by PLT count at baseline and by the several treatment previously received. Non-haematologic toxicity: 1 febrile neutropenia and 1HZV at 2nd level; 1 febrile neutropenia, 1 G3 liver toxicity, 1 bacterial pneumonia, 1HZV, 1HCV reactivation (pt died 4 months after treatment) at the 3rd level. 13/14pts are evaluable for response: 6CR, 2PR, 5PD. Conclusions: Zevalin at myeloablative activity with PBSC is feasible. It could be safely delivered in elderly and heavily pretreated pts, including those who previously received HDCT. Efficacy and mild toxicities suggest further investigation. We are continuing enrollment, including pts who previously received no more than 2 lines of CT. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Vanazzi
- European Institute of Oncology, Milan, Italy
| | - P. Ferrucci
- European Institute of Oncology, Milan, Italy
| | - C. Grana
- European Institute of Oncology, Milan, Italy
| | | | - M. Chinol
- European Institute of Oncology, Milan, Italy
| | - S. Papi
- European Institute of Oncology, Milan, Italy
| | | | - D. Radice
- European Institute of Oncology, Milan, Italy
| | | | | |
Collapse
|
47
|
Didier F, Scaffidi E, Leida E, Lupo F, Radice D, Luini A, Galimberti V, Gatti G, Martella S, Petit J. Assessment of patients' satisfaction with cosmetic results, impact on body image and sexuality after mastectomy and immediate plastic surgery with nipple preservation. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80267-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
48
|
Antognoni P, Zerini D, Gandini S, Radice D, Monti L, Ciocca M, Orecchia R. Independence of Set-up Errors From the Radiation Technologists Staff in Prostate Cancer 3D-Conformal Radiotherapy (3D-CRT) Using a No-Action Level (NAL) off-line Correction Protocol: Results From a Retrospective Analysis on Set-up Accuracy in 55 Consecutive Patients. Int J Radiat Oncol Biol Phys 2005. [DOI: 10.1016/j.ijrobp.2005.07.914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Abstract
We assessed the self-perceived health status of people with multiple sclerosis (MS) living in the Province of Milan, and the consequences of the disease on family, social and occupational status, using a cross-sectional mail survey. We identified 1350 adults with MS living in the Province of Milan. To a random sample of 400 of these, we sent out the multiple sclerosis quality-of-life-54 questionnaire (MSQOL-54), the proxy version of the short form-36 (SF-36), and a sociodemographic and clinical questionnaire. We received 261 replies (65%). Demographic and clinical data of responders and non-responders were similar except for frequency of hospitalisation over the last year, which was higher in responders. Compared to Italian norms, the MS patients had lower scores in all SF-36 domains; the differences were greatest for physical function, physical role limitations, vitality, and general health perceptions. Unemployment was 103 (41%) overall, 45% in women, and 54% in the less educated. A proxy informant was available for 245 (96%) responders. Concordance between patient and proxy reports on the SF-36 was moderate to excellent. MS had a pervasive impact on patients' lives, with substantial negative consequences for family and working life, that generally make themselves felt in the most active and productive period of people's live.
Collapse
Affiliation(s)
- A Solari
- Laboratory of Epidemiology, C. Besta National Neurologic Institute, Milan, Italy
| | | |
Collapse
|
50
|
Abstract
BACKGROUND The objective of this study was to determine the potential economic implications resulting from using exemestane (EXE), a new steroidal, irreversible aromatase inactivator, compared with megestrol acetate (MA) in patients with advanced breast carcinoma. METHODS The model used the clinical results from the manufacturer-sponsored, international, randomized, controlled, double-blind trial of patients with postmenopausal, tamoxifen-refractory advanced breast carcinoma. Seven hundred sixty-nine women were randomized to EXE 25 mg per day or MA 40 mg four times daily EXE was well tolerated, significantly delayed tumor progression (relative risk [RR], 0.82; 95% confidence interval [95% CI], 0.70-0.97), and prolonged survival (RR, 0.77; 95% CI, 0.59-0.99). Lifetime effectiveness projections were made using the trial efficacy results to the U.S. market using a 1000-day ( approximately 3-year) time frame. Because the median survival of patients who received EXE was not reached, it was projected from the Cox model. There were no differences in the rate of hospitalization. The average wholesale prices for EXE and MA were used. RESULTS Patients who received EXE were projected to have a mean survival benefit of 53.5 days (estimated 95% CI, 2-100 days) and to incur at an additional cost of $1559 per patient (estimated 95% CI, 880-2075 dollars). The incremental cost effectiveness (CE) ratio using EXE was 10,600 dollars per life year gained (estimated 95% CI, 6200-209,000 dollars). If MA had no costs, then the CE ratio increased to 12,200 dollars per life year. Using a 5-year projection, the CE ratio for EXE was 5900 dollars per life year. The projected survival at 1000 days was 53.9% in the EXE cohort compared with 44.8% in the MA cohort. CONCLUSIONS EXE, compared with MA, is projected to increase survival at a modest added cost. If treatment with EXE delays or defers initiating more costly therapies, then it may even be cost saving.
Collapse
Affiliation(s)
- B E Hillner
- Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA 23298-0170, USA.
| | | |
Collapse
|